Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes.
The study was undertaken to assess the efficacy guargum, Acarbose and their combination in modifying the sucrose absorption in patients of non Insulin dependent diabetes mellitus (NIDDM). Fifty patients of NIDDM were randomly distributed in three groups. Group A had 20 patients who received 20 grams of guargum, Group B had 10 patients who received 100 mg of Acrabose, Group C had 20 patients who received 10 grams of guargum and 50 grams of Acrabose. All the patients underwent 50 grams sucrose tolerance test with and without the trial drugs. Blood glucose levels were determined at 0, 30, 60, 90 and 120 minutes after sucrose loading. With the drugs, there was a significant decrease in the blood glucose levels at all time intervals (p < 001) in all the three groups. In all the three groups the blood glucose levels with the trial drugs was significantly lower (p < 001) than without the drug. It was seen that acarbose alone and guargum alone did not differ significantly in reducing the blood sugar level whereas combination of two produced significantly greater reduction in blood glucose levels than either of the drug used alone. Thus both guargum and acarbose are equally effective in modifying the absorption of sucrose. When combined in half the dosage they have synergistic effect and the reduction in blood glucose level is greater than either of the drug used alone.
Shah
P K
PK
Department of Medicine, Dr. SN Medical College, Jodhpur, Rajasthan, India.
Lakhotia
M
M
Purohit
A
A
Jain
S K
SK
Gupta
S K
SK
Bhandari
P
P
D020909:Acarbose; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005685:Galactans / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008351:Mannans / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D053149:Plant Gums; D013395:Sucrose; D014312:Trisaccharides / Q000009:adverse effects / Q000627:therapeutic use*
D001786:Blood Glucose; D005685:Galactans; D007004:Hypoglycemic Agents; D008351:Mannans; D053149:Plant Gums; D014312:Trisaccharides; D013395:Sucrose; C007894:guar gum; D020909:Acarbose